The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An artificial intelligence approach to variant calling of ALK resistance mutations.
 
Jochen K Lennerz
No Relationships to Disclose
 
Emily Chin
No Relationships to Disclose
 
Marguerite Rooney
No Relationships to Disclose
 
Michael Zomnir
No Relationships to Disclose
 
Enrique Dominguez Meneses
Employment - Boston Lighthouse Innovations; InTouch Health (I)
Stock and Other Ownership Interests - Boston Lighthouse Innovations; InTouch Health (I)
 
Lev Lipkin
Stock and Other Ownership Interests - Novartis; Pfizer
 
A. John Iafrate
Stock and Other Ownership Interests - Archer
Consulting or Advisory Role - Chugai Pharma; Debiopharm Group; Roche
Research Funding - Blueprint Medicines
Patents, Royalties, Other Intellectual Property - ArcherDx exclusive license to AMP technology
 
Long P. Le
Stock and Other Ownership Interests - Archer
Consulting or Advisory Role - Archer
Patents, Royalties, Other Intellectual Property - I am a co-inventor of the Anchored Multiplex PCR technology which is licensed to ArcherDx. I receive royalty payments for this patent.
Travel, Accommodations, Expenses - Archer
 
Alice Tsang Shaw
Honoraria - Foundation medicine; Guardant Health; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Bayer; Blueprint Medicines; Chugai Pharma; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - ARIAD (Inst); Daiichi Sankyo (Inst); Ignyta (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); TP Therapeutics (Inst)